Search results
Results from the WOW.Com Content Network
A bone scan or bone scintigraphy / s ɪ n ˈ t ɪ ɡ r ə f i / is a nuclear medicine imaging technique used to help diagnose and assess different bone diseases. These include cancer of the bone or metastasis, location of bone inflammation and fractures (that may not be visible in traditional X-ray images), and bone infection (osteomyelitis). [1]
A CT scan, MRI, or 3-phase bone scan may be more effective for early diagnosis. [7] MRI appears to be the most accurate diagnostic test. [8] Tuning forks have been advocated as an inexpensive alternative for identifying the presence of stress fractures. The clinician places a vibrating tuning fork along the shaft of the suspected bone.
Osteolytic lesion at the bottom of the radius, diagnosed by a darker section that indicates a loss of bone density. An osteolytic lesion (from the Greek words for "bone" (ὀστέον), and "to unbind" (λύειν)) is a softened section of a patient's bone formed as a symptom of specific diseases, including breast cancer and multiple myeloma.
REMS processes the raw, unfiltered ultrasound signals acquired during an echographic scan of the axial sites, femur and spine. The analysis is performed in the frequency domain. Bone mineral density is estimated by comparing the results against reference models. The accuracy has been tested by comparing it against to DXA technology. [1] [2] [3] [4]
99m Tc-MDP must be prepared in a radiopharmacy.It is usually supplied as a "cold kit" to which radioactive 99m Tc from a generator is added. Kit composition may vary between suppliers, but contents typically includes medronic acid, stannous chloride dihydrate and sometimes ascorbic acid. [4]
For premium support please call: 800-290-4726 more ways to reach us
The standard in bone mineral density scanning developed in the 1980s is called Dual X-ray Absorptiometry, known as DXA. The DXA technique uses two different x-ray energy levels to estimate bone density. DXA scans assume a constant relationship between the amounts of lean soft tissue and adipose tissue.
Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. [1] The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.